Ash 2021 – Sanofi takes its time with fitusiran
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
Ash 2021 – Global Blood stems the bleeding
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Ash 2021 – Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging, but a filing is a way away.
Ash 2021 – Agios and Forma take different paths in sickle cell disease
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
